NYSE$JNJ

Johnson & Johnson · Q2 2026 earnings

Q2 2026 earnings · · Before market open · Investor relations

Briefing

Johnson & Johnson reported Q2 2026 sales of $25.3 billion with adjusted EPS of $2.90 and raised full-year guidance.

Johnson & Johnson delivered 6.6% reported sales growth to $25.3 billion in Q2 2026, driven by strong performance in Innovative Medicine and MedTech. Net earnings were $5.5 billion with adjusted net earnings rising 5.7% to $7.1 billion. The company raised its 2026 full-year outlook, citing robust pipeline momentum and operational execution.

  • Worldwide sales grew 6.6% reported and 5.7% adjusted operational to $25.3 billion.
  • Adjusted EPS increased 4.7% to $2.90 while GAAP EPS was $2.27.
  • Innovative Medicine operational sales rose 6.8% and MedTech rose 3.6%.
  • Full-year 2026 guidance raised to $101.1 billion sales and $11.68 adjusted EPS at midpoint.

Headline financials

Total Revenue

$25.3B

Previous: $23.7B+6.6%
EPS (adj)

$2.90

Previous: $2.29+26.6%
Adjusted Net Earnings

$7.08B

No prior period
Adjusted Operational Sales Growth

5.7%

No prior period
Free Cash Flow

$8.7B

Previous: $3.7B+135.2%
Net Income

$5.53B

Previous: $5.54B-0.1%

Revenue & EPS history

Johnson & Johnson · Revenue · Quarterly

$25.3B

Q2 2026+6.6%vs Q2 2025
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Johnson & Johnson · $25.3B total across 2 segments · Q2 2026

  • Innovative Medicine
    $16.4B
  • MedTech
    $8.93B

Forward guidance

Company raised 2026 guidance with estimated reported sales of $101.1 billion (7.3% growth) and adjusted EPS of $11.68 (8.2% growth) at the midpoint.

Tailwinds

  • Raised adjusted operational EPS midpoint by $0.18 to $11.58
  • Pipeline advancing with multiple regulatory approvals and data readouts
  • On track to exceed $100 billion annual revenue for first time

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

+0.4%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+0.8%

Avg return

30 days after

54%

37 / 69 earnings

Positive

+7.2%

Q2 2023

Best reaction

-4.1%

Q4 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+0.0%-1.6%-3.8%
Q4 2025-0.4%+1.5%+11.1%
Q3 2025+0.1%+1.2%+2.3%
Q2 2025+0.9%+2.0%+3.1%
Q1 2025-0.5%+2.0%-3.1%
Q4 2024-1.9%+3.2%+9.6%
Q3 2024+1.7%+2.2%-6.0%
Q2 2024+2.9%+2.1%+5.5%
Q1 2024-1.9%+0.2%+4.5%
Q4 2023-2.2%-1.8%-1.2%
Q3 2023-3.0%-2.9%-4.7%
Q2 2023+7.2%+8.6%+8.7%
Q1 2023-1.9%-1.8%-4.3%
Q4 2022+0.7%-0.0%-6.3%
Q3 2022-1.1%+1.3%+5.0%
Q2 2022-2.0%-1.2%-4.3%
Q1 2022+3.5%+2.2%-2.1%
Q4 2021+3.3%+5.4%-3.0%
Q3 2021+2.3%+2.2%+1.4%
Q2 2021+0.9%+2.0%+6.5%
Q1 2021+2.4%+1.7%+5.2%
Q4 2020+1.1%-1.7%-1.9%
Q3 2020-2.5%-2.5%-2.3%
Q2 2020+0.7%+1.0%-0.0%
Q1 2020+5.6%+8.8%+5.6%
Q4 2019-0.5%-0.3%+0.4%
Q3 2019+3.4%-2.3%+0.2%
Q2 2019-2.1%-3.3%-3.1%
Q1 2019+1.5%+0.7%+1.2%
Q4 2018-1.4%-1.9%+3.6%
Q3 2018+4.1%+3.8%+7.9%
Q2 2018+2.5%+0.9%+6.2%
Q1 2018-3.1%-3.9%-6.0%
Q4 2017-4.1%-1.9%-12.3%
Q3 2017+3.3%+4.6%+2.0%
Q2 2017+2.3%+2.4%+0.7%
Q1 2017-3.5%-3.1%+1.0%
Q4 2016-1.0%-0.5%+6.8%
Q3 2016-3.3%-4.3%-1.6%
Q2 2016+1.6%+1.5%-2.0%
Q1 2016+2.4%
Q4 2015+6.0%
Q3 2015-1.5%
Q2 2015+0.1%
Q1 2015+0.0%
Q4 2014-2.1%
Q3 2014-0.9%
Q2 2014-3.0%
Q1 2014+1.7%
Q4 2013-0.8%
Q3 2013+1.5%
Q2 2013-0.3%
Q1 2013+2.7%
Q4 2012-0.5%
Q3 2012+3.5%
Q2 2012+1.3%
Q1 2012-1.1%
Q4 2011+2.0%
Q3 2011-0.6%
Q2 2011-1.5%
Q1 2010+2.1%
Q1 2011-0.6%
Q4 2007+0.7%
Q4 2010+0.7%
Q3 2008+1.8%
Q3 2010+1.8%
Q2 2010-1.1%
Q4 2008-1.1%
Q2 2008-1.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro